Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Urol Oncol. 2020 Feb;38(2):41.e11-41.e18. doi: 10.1016/j.urolonc.2019.07.006. Epub 2019 Aug 2.
To investigate the expression pattern of CD155 and evaluate the prognostic value of CD155 in muscle-invasive bladder cancer (MIBC).
Immunohistochemical staining of CD155 and survival analysis were conducted on 228 nonmetastatic MIBC patients underwent radical cystectomy in cohorts from Fudan University Shanghai Cancer Center and Zhongshan Hospital. Association of CD155 gene expression with tumor stage and survival were analyzed in TCGA and GSE13507 dataset.
CD155 was significantly up-regulated in MIBC compared to matched normal urothelium and majorly stained on the membrane of tumor cells. In Fudan MIBC cohort, CD155 high expression was significantly correlated with shorter recurrence-free survival (HR = 2.13, P < 0.001) and overall survival (HR = 2.49, P < 0.001). CD155 expression, T stage, and lymph node status were independent factors for predicting survival in multivariate analysis. In TCGA dataset, CD155 high expression was independently associated with shorter overall survival (HR = 1.74, P = 0.001) beyond age, T stage, and lymph node status. Further, explorative analysis in Fudan MIBC cohort showed that adjuvant chemotherapy was associated with longer recurrence-free survival and overall survival in stage III and IV disease with CD155-high tumors.
These findings suggest that CD155 is a robust prognostic factor and may help predict the benefit of adjuvant chemotherapy in MIBC.
研究 CD155 的表达模式，并评估其在肌层浸润性膀胱癌（MIBC）中的预后价值。
本研究对复旦大学附属肿瘤医院和中山大学附属第一医院的 228 例接受根治性膀胱切除术的非转移性 MIBC 患者的 CD155 进行了免疫组织化学染色和生存分析。在 TCGA 和 GSE13507 数据集分析中，分析了 CD155 基因表达与肿瘤分期和生存的相关性。
与配对的正常尿路上皮相比，CD155 在 MIBC 中显著上调，主要在肿瘤细胞的膜上染色。在复旦大学 MIBC 队列中，CD155 高表达与较短的无复发生存（HR=2.13，P<0.001）和总生存（HR=2.49，P<0.001）显著相关。在多因素分析中，CD155 表达、T 分期和淋巴结状态是预测生存的独立因素。在 TCGA 数据集，CD155 高表达与较短的总生存独立相关（HR=1.74，P=0.001），超过了年龄、T 分期和淋巴结状态。此外，在复旦大学 MIBC 队列的探索性分析中，CD155 高肿瘤的 III 期和 IV 期疾病患者接受辅助化疗与无复发生存和总生存时间延长相关。
这些发现表明 CD155 是一个强有力的预后因素，可能有助于预测 MIBC 辅助化疗的获益。
